GIP receptors and brain dopamine in mice

Researchers at the University of Alabama at Birmingham have found receptors for a second gut hormone sitting in a brain region already tied to reward. In a letter published in ACS Chemical Neuroscience on 1 June 2026, the team reports that glucose-dependent insulinotropic polypeptide receptors are present in the lateral septum of mice, on many of the same cells that carry GLP-1 receptors, and that a GIP receptor agonist reduces electrically evoked dopamine release there^[1]. That is the GIP half of a dual agonist such as tirzepatide acting on dopamine signalling. It is also an experiment in twenty anaesthetised mice, which is where the caution starts.

What the study measured

Two techniques did the work. RNAscope, which labels individual messenger RNA molecules inside tissue sections, mapped which genes were switched on in which cells. Fast scan cyclic voltammetry, an electrochemical method that detects dopamine at high temporal resolution, measured dopamine release in living animals^[1].

The mapping came first. Gipr expression was enriched in both the dorsal and the intermediate lateral septum. In the dorsal portion, 37.1% of Glp1r-positive neurons also expressed Gipr. In the intermediate portion the figure was 18.1%^[1]. A separate set of sections showed that a share of Glp1r-positive cells in both subregions also carry Drd2, the gene for the dopamine D2 receptor^[1].

Then came the electrodes. A carbon fibre microelectrode went into the caudal lateral septum and a stimulating electrode into the medial forebrain bundle, so release could be triggered on demand and watched as it happened. Mice received a subcutaneous injection of vehicle, semaglutide, a GIP receptor agonist called [d-Ala2]GIP 1-42, or both agonists together, five hours before cocaine was administered^[1].

What happened to dopamine

All three active treatments significantly reduced the maximum electrically evoked dopamine release compared with vehicle. Only the combination of semaglutide and the GIP receptor agonist significantly reduced the total amount of dopamine released, measured as area under the curve, when no cocaine was on board^[1].

Cocaine was the second half of the design. It blocks dopamine reuptake and pushes extracellular dopamine up, which is the pharmacology underneath its reinforcing effect. All three treatments significantly reduced cocaine's ability to raise both the peak evoked signal and the overall amount of extracellular dopamine^[1]. Neither agonist on its own changed dopamine clearance in the presence of cocaine, though the combination did^[1].

Each of the four treatment groups held five mice, twenty animals in total, and every mouse received cocaine^[1].

Why the lateral septum

The lateral septum is not the obvious place to look for an appetite drug's mechanism, which is part of what makes the finding interesting. It is a mostly GABAergic hub that links the hippocampus to a range of subcortical targets and has been implicated in reward, feeding, anxiety, fear, sociability and memory, with dorsal and ventral poles that often pull in opposite directions^[3]. One of its outputs runs to the ventral tegmental area, a dopamine node^[1].

The same group laid the groundwork years ago. A 2016 paper in Translational Psychiatry reported that GLP-1 receptor activation regulates cocaine's actions and dopamine homeostasis in the lateral septum^[2], following a 2013 report that the GLP-1 analogue exendin-4 attenuated the rewarding effects of cocaine in mice^[5]. What the new letter adds is the GIP receptor. Nobody had shown it was there, on those cells, with that effect.

What this is not

This is not a human result, and nothing in it tells a patient anything about their own treatment. The dopamine recordings were taken from anaesthetised male mice, with an electrode driving release artificially rather than an animal choosing to eat or to seek a drug^[1]. Feeding behaviour was not measured, and neither was food preference. At no stage was a human involved.

The authors are open about the limits. They write that their sample size might not have been sufficient to detect regulation of dopamine clearance, and that because they did not hypothesise sex differences in this region, the experiments were performed mainly in male mice^[1]. On appetite they go no further than a stated guess: "It is tempting to speculate that these data point to a new mechanism of how tirzepatide might regulate caloric intake and food preference."^[1]

Tempting to speculate is not evidence. If you are reading this because you take a GLP-1 or dual agonist, or are considering one, the honest summary is that this study changes nothing about what is known clinically.

Where it connects to tirzepatide

Tirzepatide is why this line of work has an audience outside neuroscience. It is a once-weekly agonist at both the GIP and the GLP-1 receptor, authorised in the EU as Mounjaro for type 2 diabetes and for weight management, and the EMA's own product overview notes that the hormones it mimics bind receptors in the brain as well as the pancreas, and that targeting those receptors reduces appetite^[4]. What that overview does not do, because nobody had established it, is name the circuits.

For most of the class's history the GLP-1 arm has carried the explanation and the GIP arm has been the part nobody could fully account for. A rodent finding that GIP receptors sit on lateral septum neurons alongside GLP-1 receptors, near cells carrying D2 receptors, and that agonism there suppresses evoked dopamine, is a candidate mechanism for what the GIP component contributes. Candidate is the operative word. Our tirzepatide page sets out what the clinical trial programme has actually established, and the regulation section covers where the drug is licensed.

It is worth keeping this separate from the "food noise" conversation as well. We went through the five competing theories of what food noise is, and none of them has been settled. A dopamine recording in an anaesthetised mouse does not pick between them.

What we don't yet know

The authors name their own next steps: whether activating GIP receptors locally in the septum, rather than systemically, produces the same effect, and whether female mice respond the way male mice did^[1]. Past that, the distance between a suppressed voltammetry signal in an anaesthetised mouse and a person eating less is large, and nobody has crossed it. Whether GIP receptor agonism has any measurable effect on human reward processing is untested.

The application the authors raise is not obesity at all. There is no approved medicine for cocaine use disorder, and they point to combined GLP-1 and GIP receptor agonism as a possible target^[1]. That would need clinical trials that have not begun.

This article is for educational and journalistic purposes and is not medical advice. Preclinical mechanism work is how new treatments start, and it is also where most of them stop. Any question about tirzepatide or another prescription medicine belongs with a clinician who knows your history.